NasdaqGS:BIIBBiotechs
Biogen (BIIB) And The Alzheimer’s Narrative As Valuation Stays In Focus
Biogen (BIIB) is back in focus after recent share price moves and fresh attention on its neurology focused drug portfolio. Investors are weighing current performance metrics against the company’s latest collaborations and therapy approvals.
See our latest analysis for Biogen.
At a share price of US$221.56, Biogen has shown firm momentum, with a 1 month share price return of 10.81%, year to date share price return of 24.60%, and a 1 year total shareholder return of 59.41%, despite weaker total...